Stay updated on IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.

Latest updates to the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedFooter now shows Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedThe page's revision label updated from v3.2.0 to v3.3.2, a minor version change with no impact on study content, eligibility, or function. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedRemoved the funding/operational status notice that previously appeared on the page; study details and other content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check69 days agoChange DetectedThe new screenshot shows a redesigned layout and styling on the ClinicalTrials.gov study page, with the same study details, eligibility criteria, and primary outcomes as before. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check98 days agoChange DetectedCore update: add a government funding/operating status notice and bump to v3.2.0, replacing the previous v3.1.0 tag.SummaryDifference5%

- Check105 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.1%

Stay in the know with updates to IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.